Loading
Life sciences · Journal article
Bleeding Thrombosis and Vascular Biology · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background and Aims. Haemophilia A (HA) is a rare X-linked recessive bleeding disorder caused by variants in the F8 gene, which encodes coagulation factor VIII (FVIII). HA is characterized by FVIII deficiency, leading to impaired hemostasis and spontaneous bleeding episodes. In patients with HA, increasing FVIII activity above 2–5% can significantly improve quality of life. The aim of the study is to correct the F8 variant and to restore FVIII expression in a male patient with severe hemophilia A through CRISPR–Cas9 base editing in liver sinusoidal endothelial cells (LSECs).Materials and Methods. Peripheral blood stem cells were isolated and reprogrammed into induced pluripotent stem cells (iPSCs) after transduction with a non-integrative Sendai virus system. The clones obtained were stabilized, and their pluripotency was characterized by specific markers such as Oct4, Sox2, Klf4, and Nanog. Gene correction of HA-iPSCs was performed using CRISPR-Cas9 DNA base editing technology targeting the F8 variant NM_000132.4: c.6967C>T. Following editing, cells were differentiated into LSECs using an optimized differentiation protocol, and FVIII expression was assessed by immunofluorescence (IF) and real-time PCR (RT-qPCR).Results. HA-iPSCs were positive for alkaline phosphatase staining, and IF validated the expression of pluripotency markers. The differentiated LSECs were positive for FCGR2B expression, as assessed by both IF and RT-qPCR. Furthermore, embryoid body formation was performed, demonstrating the expression of markers from all three germ layers. FVIII expression in HA-derived LSECs was evaluated before and after gene editing using IF, RT-qPCR, and western blot. The gene correction was confirmed, resulting in approximately 70% restoration of FVIII levels (Figure 1).Conclusions. The iPSCs derived from the severe HA patient were successfully edited, highlighting the potential of CRISPR–Cas9 technology for future patient-specific correction of pathogenic variants. Furthermore, differentiation into LSECs proved to be a relevant and robust in vitro model for evaluating FVIII restoration in HA patients. In conclusion, given the limitations of current treatments, gene therapy may provide a promising and personalized therapeutic approach for these patients.